Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New concerns about thalidomide.

Beau M Ances1

  • 1Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. bances@mail.med.upenn.edu

Obstetrics and Gynecology
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraindividual cognitive variability predicts amyloid beta, tau PET, and dementia conversion in Down syndrome: a potential marker of cognitive resilience.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Inflammation Associated With Obesity, Aging, and Amyloid Burden in Adults With Down Syndrome.

Obesity (Silver Spring, Md.)·2026
Same author

Leveraging STRAW +10 criteria to evaluate menopause stage effects on sleep quality.

Climacteric : the journal of the International Menopause Society·2026
Same author

Circadian Rest-Activity Rhythms, Cognition, and Alzheimer Disease Dementia in Adults With Down Syndrome.

Neurology·2026
Same author

Early syndecan-4 upregulation predicts cognitive and pathological trajectories in Alzheimer disease.

Alzheimer's research & therapy·2026
Same author

History of Traumatic Brain Injury with Loss of Consciousness and APOE <i>ε</i>4 Carriers Synergistically Increase Late-Life Amyloid PET Burden.

bioRxiv : the preprint server for biology·2026
Same journal

The Political Determinants of Obstetric Prescribing.

Obstetrics and gynecology·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Adverse Maternal Pregnancy Outcomes: A Systematic Review and Meta-analysis.

Obstetrics and gynecology·2026
Same journal

Milestones in Motion: Vaginal Birth After Cesarean.

Obstetrics and gynecology·2026
Same journal

Ebola Virus in Pregnancy.

Obstetrics and gynecology·2026
Same journal

A Quality-Improvement Study Evaluating Three Postpartum Prophylactic Oxytocin Rates and Blood Loss After Vaginal Birth.

Obstetrics and gynecology·2026
Same journal

The Effects of Climate Change on Obstetric and Gynecologic Health.

Obstetrics and gynecology·2026
See all related articles

The Food and Drug Administration (FDA) approved thalidomide for erythema nodosum leprosum, reversing a 1960s ban due to birth defect risks. New guidelines aim to balance benefits against potential safety concerns.

Area of Science:

  • Pharmacology
  • Dermatology
  • Regulatory Affairs

Background:

  • Thalidomide was previously rejected by the FDA in the 1960s due to severe teratogenic effects, including birth defects and miscarriages.
  • The FDA's 1960s decision significantly impacted its reputation as a consumer safety authority.
  • Erythema nodosum leprosum (ENL) is a painful complication of leprosy.

Purpose of the Study:

  • To report the recent FDA approval of thalidomide for ENL symptom management.
  • To highlight the historical context of thalidomide's regulatory journey.
  • To address the implications of this regulatory reversal.

Main Methods:

  • Review of FDA regulatory history concerning thalidomide.
  • Analysis of the conditions and monitoring procedures accompanying the new approval.

Related Experiment Videos

  • Examination of potential benefits and risks associated with the reintroduction of thalidomide.

    • Main Results:

    • The FDA has approved thalidomide for treating painful ENL symptoms.
    • Strict guidelines and monitoring protocols are mandated for the drug's use.
    • The approval represents a significant shift in the FDA's stance on thalidomide.

    Conclusions:

    • The recent FDA approval of thalidomide for ENL offers therapeutic potential.
    • Strict regulatory measures are crucial to mitigate risks associated with thalidomide.
    • This decision necessitates careful consideration of both patient benefits and public safety.